{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:33:00Z","timestamp":1793845980321,"version":"4.6.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>With the rise in glucagon-like peptide 1 receptor agonist (GLP-1RA) medication usage for Type 2 diabetes mellitus and weight loss, concerns have been raised regarding safety and primary aspiration risk when undergoing anesthesia procedures. Given the paucity of evidence, there is concern whether patients on GLP-1RA are at higher risk of retained gastric contents and subsequent adverse outcomes during routine esophagogastroduodenoscopy (EGD). This study aims to investigate whether patients on GLP-1RA are at higher risk of retained gastric contents during routine EGD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, we examined 1,368 adult patients who underwent EGDs in the outpatient setting at a tertiary care center. A multivariable analysis was conducted to predict the presence of retained gastric contents on EGD, with the primary predictor being GLP-1RA use. Covariates thought to contribute to delayed gastric emptying were used as secondary predictors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Retained gastric contents were seen in 18 out of 128 cases in the GLP-1RA users (14.1%), which was statistically significant when compared to 45 out of the 1,156 non-users (3.8%) (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, LR 18.323). There was no significant increase in adverse outcomes associated with this finding. GLP-1RA use (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, OR = 5.4), history of gastroparesis (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, OR = 4.55), chronic kidney disease (<jats:italic>p<\/jats:italic> = 0.036, OR = 3.47) and hemiplegia (<jats:italic>p<\/jats:italic> = 0.048, OR = 2.9) increased risk of retained gastric contents. In contrast, bowel prep (<jats:italic>p<\/jats:italic> = &amp;lt; 0.001, OR = 0.157) for same day lower GI procedures decreased risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results show an increase in retained gastric contents in GLP-1RA users undergoing EGD. Other mitigating factors and whether the increase results in aspiration complications should be further studied.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1638981","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:23:33Z","timestamp":1757481813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["GLP-1 receptor agonist increase retained gastric contents on EGD and same-day colonoscopy reduces this risk"],"prefix":"10.3389","volume":"12","author":[{"given":"Dirin","family":"Ukwade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeel","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan S.","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexter","family":"Nwachukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paya","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Boulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece A.","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr Atheroscler Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther."},{"key":"B3","volume-title":"Compare and Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)","author":"Latif","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e29262","DOI":"10.7759\/cureus.29262","article-title":"FDA-Approved pharmacotherapy for weight loss over the last decade","volume":"14","author":"Idrees","year":"2022","journal-title":"Cureus."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S297","DOI":"10.37765\/ajmc.2022.89293","article-title":"Semaglutide 2.4-mg injection as a novel approach for chronic weight management","volume":"28","author":"Kyrillos","year":"2022","journal-title":"Am J Manag Care."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report","volume":"70","author":"Gulak","year":"2023","journal-title":"Can J Anaesth."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anaesth."},{"key":"B9","unstructured":"Joshi\n              GP\n            \n            \n              Abdelmalak\n              BB\n            \n            \n              Weigel\n              WA\n            \n            \n              Soriano\n              SG\n            \n            \n              Harbell\n              MW\n            \n            \n              Kuo\n              CI\n            \n          \n          American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor\n          \n          2023"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","author":"Kindel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.gie.2017.07.018","article-title":"Guidelines for sedation and anesthesia in GI endoscopy","volume":"87","author":"Early","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.gie.2022.04.024","article-title":"Adverse events associated with EGD and EGD-related techniques","volume":"96","author":"Coelho-Prabhu","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"111091","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth."},{"key":"B14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/jdi.14005","article-title":"Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy","volume":"14","author":"Kobori","year":"2023","journal-title":"J Diabetes Investig."},{"key":"B15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/10600280211055804","article-title":"Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD)","volume":"56","author":"Stark","year":"2022","journal-title":"Ann Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.cgh.2024.07.021","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis","volume":"23","author":"Facciorusso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.14309\/ajg.0000000000002820","article-title":"Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management","volume":"119","author":"Hiramoto","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.14309\/ajg.0000000000002969","article-title":"Glucagon-like peptide receptor agonists use before endoscopy is associated with low retained gastric contents: a multicenter cross-sectional analysis","volume":"120","author":"Phan","year":"2025","journal-title":"Am J Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrgastro.2018.7","article-title":"International working group for disorders of gastrointestinal motility and function. Expert consensus document: advances in the diagnosis and classification of gastric and intestinal motility disorders","volume":"15","author":"Keller","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e143771","DOI":"10.1172\/JCI143771","article-title":"Gastrointestinal motility disorders in neurologic disease","volume":"131","author":"Camilleri","year":"2021","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4386025","DOI":"10.1155\/2018\/4386025","article-title":"Advanced biventricular heart failure due to left ventricular noncompaction cardiomyopathy leading to the formation of a gastric bezoar: the implications of heart failure on the gastrointestinal tract","volume":"2018","author":"Yunina","year":"2018","journal-title":"Case Rep Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cgh.2008.11.022","article-title":"Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis","volume":"7","author":"Kalaitzakis","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/0886022X.2022.2030754","article-title":"Delayed gastric emptying in nondiabetic patients with end-stage kidney disease","volume":"44","author":"Wang","year":"2022","journal-title":"Ren Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"116342","DOI":"10.1016\/j.ejmech.2024.116342","article-title":"Glucagon-like peptide-1 analogs: miracle drugs are blooming?","volume":"269","author":"Gong","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2337\/db13-0893","article-title":"Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia","volume":"63","author":"Umapathysivam","year":"2014","journal-title":"Diabetes"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2436783","DOI":"10.1001\/jamanetworkopen.2024.36783","article-title":"Food retention at endoscopy among adults using glucagon-like peptide-1 receptor agonists","volume":"7","author":"Nasser","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.gie.2008.05.057","article-title":"The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research","volume":"69","author":"Lai","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gie.2024.01.012","article-title":"The prospective validation of a scoring system to assess mucosal cleanliness during EGD","volume":"100","author":"Roma\u0144czyk","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jgh.15662","article-title":"Scoring system assessing mucosal visibility of upper gastrointestinal tract: the POLPREP scale","volume":"37","author":"Roma\u0144czyk","year":"2022","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1638981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:23:35Z","timestamp":1757481815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1638981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1638981"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1638981","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1638981"}}